Clinical Research Directory

Inclusion Criteria: * Accept participation in the study by signing informed consent * Age ≥18 years old * People who consider themselves men who have sex with men or transgender women * All eligible people with HIV must meet the following: 1. stable antiretroviral treatment during the last 6 months and with undetectable viral load (depending on the method used for measurement) within the same period (the participant can bring a laboratory report carried out in the last 6 months). Regarding ART, a change associated with toxicity or simplification may be allowed before 12 weeks of the selection visit, with undetectable VL between 12 weeks and the selection visit; and 2. CD4 cell count ≥ 200 cells/ml in the last 6 months (participant can bring a laboratory report from the last 6 months) Exclusion Criteria: * Have a history or current suspicion of cancer * Have a known history or current suspicion of high-grade lesion or anal intraepithelial neoplasia related to HPV. * Have received any dose of HPV vaccine at some time in your life. * Have received any vaccine in the last 30 days. * Have a known allergy to any of the components of the HPV vaccine. * Have a history of a previous severe allergic reaction, regardless of the cause. * Presenting an acute illness that could alter the study evaluations or could put the participant at risk, according to the researcher\'s criteria. * Present chronic or acute immunosuppression (except HIV). * Have received antineoplastic and immunomodulatory agents or radiotherapy in the 6 months prior to the study or plan to receive these treatments during the study period. * Having chronic diseases without adequate control. * Have a diagnosis of ongoing malignant disease. * Having received immunoglobulins, blood or blood products in the last 3 months. * Do not participate in another intervention study * That he is not an employee or first-degree relative of any member of the institution. * Any condition or clinical situation where it is considered that participation in the study may pose a risk to the patient.\* \* People with chronic HBV infection, who are receiving treatment and have normal transaminases for the last 6 months can be included in the study. People with chronic HCV infection can enter the study if they have normal transaminases for the last 6 months and do not plan to start treatment during the study. In either case, transaminases can be requested through the study if they are not available.